You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Financial news, mergers and acquisitions, partnerships, and alliances.
Following a positive interim analysis of the Phase III OVAL trial, Japan-based NanoCarrier plans to open trial sites for VBL Therapeutics' VB-111.
The European Commission will now consider whether to grant marketing authorization to the drug regimen.
Under the agreement, AstraZeneca will be able to use ImaginAb's CD8 ImmunoPET technology in its clinical trials in North America and Europe.
A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.
The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.